New injection aims to tackle Alzheimer's at its roots
NCT ID NCT07221344
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called ARO-MAPT-SC in healthy people and those with early Alzheimer's. The goal is to check if it is safe and how the body processes it. Participants receive either the drug or a placebo by injection under the skin. The trial is still in early stages, so it focuses on safety and dosing, not yet on curing the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARO-MAPT-SC (a drug given by injection under the skin)
What this could lead to
If successful, this could point toward a treatment that slows or stops early Alzheimer's disease by targeting a key protein in the brain.
What could go wrong
This is an early-phase trial with only 112 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site 1
RECRUITINGGrafton, Auckland, 1010, New Zealand
-
Research Site 2
RECRUITINGToronto, Ontario, M3B2S7, Canada
-
Research Site 3
RECRUITINGEast York, Ontario, M4G 3E8, Canada